PMID- 27070835
OWN - NLM
STAT- MEDLINE
DCOM- 20161223
LR  - 20161230
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 90
IP  - 5
DP  - 2016
TI  - Assessment of Adrenal Function and Health-Related Quality of Life in Advanced 
      Gastric Cancer Patients Who Received First-Line Chemotherapy.
PG  - 248-54
LID - 10.1159/000445010 [doi]
AB  - OBJECTIVE: We performed this prospective study to identify both the incidence of 
      adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced 
      gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) 
      regimen as a first-line palliative chemotherapy. METHODS: We assessed adverse 
      events (AEs) observed in 52 patients who received the SP regimen for AGC between 
      January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events 
      (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after 
      chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. 
      HRQOL was assessed using the European Organization for Research and Treatment of 
      Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). RESULTS: The 
      incidence of AI was 30.8% (n = 16) and of AE observed 55% (n = 29) among 52 
      patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4% (n = 10) 
      were diagnosed with AI, and of 23 patients without AE, 26.1% (n = 6) were 
      diagnosed with AI. CONCLUSION: The incidence of secondary AI in AGC patients was 
      not rare and was not correlated with the presence of nonspecific AEs. Although 
      patients diagnosed with AI did not show any related symptoms, they are at risk of 
      potentially life-threatening consequences. Thus, the evaluation of AI could be 
      suggested for patients who received chemotherapy.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Kim, Hye Ryun
AU  - Kim HR
AD  - College of Medicine, Yonsei University Graduate School, Seoul, Korea.
FAU - Kim, Jee Hung
AU  - Kim JH
FAU - Rhee, Yumie
AU  - Rhee Y
FAU - Lee, Hosun
AU  - Lee H
FAU - Song, Seung Eun
AU  - Song SE
FAU - Kim, Chan
AU  - Kim C
FAU - Song, Sukyung
AU  - Song S
FAU - Noh, Sung Hoon
AU  - Noh SH
FAU - Rha, Sun Young
AU  - Rha SY
LA  - eng
PT  - Journal Article
DEP - 20160413
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Biomarkers)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - Q20Q21Q62J (Cisplatin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adrenal Glands/*drug effects/*metabolism
MH  - Adrenal Insufficiency/*blood/*chemically induced/physiopathology
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects
MH  - Biomarkers/blood
MH  - Chemotherapy, Adjuvant
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Female
MH  - Gastrectomy
MH  - Health Status
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Oxonic Acid/administration & dosage/adverse effects
MH  - Pilot Projects
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Stomach Neoplasms/*drug therapy/physiopathology
MH  - Tegafur/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2016/04/14 06:00
MHDA- 2016/12/24 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/11/17 00:00 [received]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/12/24 06:00 [medline]
AID - 000445010 [pii]
AID - 10.1159/000445010 [doi]
PST - ppublish
SO  - Oncology. 2016;90(5):248-54. doi: 10.1159/000445010. Epub 2016 Apr 13.